Sales Virna L, Mettler Bret A, Lopez-Ilasaca Marco, Johnson John A, Mayer John E
Department of Cardiovascular Surgery, Children's Hospital, Boston, Massachusetts 02115, USA.
Tissue Eng. 2007 Mar;13(3):525-35. doi: 10.1089/ten.2006.0128.
An unresolved question regarding tissue-engineered (TE) cardiac valves and vessels is the fate of the transplanted cells in vivo. We have developed a strategy to track the anatomic location of seeded cells within TE constructs and neighboring tissues using a retroviral vector system encoding green and red fluorescent proteins (GFPs and RFPs, respectively) in ovine circulating endothelial progenitor cells (EPCs) and bone marrow-derived mesenchymal stem cells (BMSCs). We demonstrate that stable transduction ex vivo with high-titer Moloney murine leukemia virus-based retroviral vector yields transduction efficiency of greater than 97% GFP(+) EPC- and RFP(+) mesenchymal stem cell (MSC)-derived cells. Cellular phenotype and transgene expression were also maintained through 25 subsequent passages. Using a retroviral vector system to distinguish our pre-seeded cells from tissue-resident progenitor cells and circulating endothelial and marrow-derived precursors, we simultaneously co-seeded 2 x 10(6) GFP(+) EPCs and 2 x 10(5) RFP(+) MSCs onto the TE patches. In a series of ovine pulmonary artery patch augmentation studies, transplanted GFP(+) EPC- and RFP(+) MSC-derived cells persisted within the TE patch 7 to 14 days after implantation, as identified using immunofluorescence. Analysis showed 81% luminal coverage of the TE patches before implantation with transduced cells, increasing to 96% at day 7 and decreasing to 67% at day 14 post-implantation. This suggests a temporal association between retroviral expression of progenitor cells and mediating effects of these cells on the physiological remodeling and maturation of the TE constructs. To our knowledge, this is the first cardiovascular tissue-engineering in vivo study using a double-labeling method to demonstrate a direct evidence of the source, persistence, and incorporation into a TE vascular patch of co-cultured and simultaneously pre-seeded adult progenitor cells.
关于组织工程化(TE)心脏瓣膜和血管的一个尚未解决的问题是移植细胞在体内的命运。我们已经开发出一种策略,利用一种逆转录病毒载体系统来追踪TE构建体及邻近组织中接种细胞的解剖位置,该逆转录病毒载体系统分别在绵羊循环内皮祖细胞(EPC)和骨髓间充质干细胞(BMSC)中编码绿色和红色荧光蛋白(分别为GFP和RFP)。我们证明,用基于莫洛尼鼠白血病病毒的高滴度逆转录病毒载体进行体外稳定转导,可使GFP(+)EPC和RFP(+)间充质干细胞(MSC)来源的细胞转导效率大于97%。细胞表型和转基因表达在随后的25代中也得以维持。利用逆转录病毒载体系统将我们预先接种的细胞与组织驻留祖细胞以及循环内皮和骨髓来源的前体细胞区分开来,我们将2×10⁶个GFP(+)EPC和2×10⁵个RFP(+)MSC同时共接种到TE补片上。在一系列绵羊肺动脉补片增大研究中,植入后7至14天,移植的GFP(+)EPC和RFP(+)MSC来源的细胞持续存在于TE补片中,这是通过免疫荧光鉴定的。分析显示,植入前转导细胞对TE补片的管腔覆盖率为81%,植入后第7天增加到96%,第14天降至67%。这表明祖细胞的逆转录病毒表达与这些细胞对TE构建体的生理重塑和成熟的介导作用之间存在时间关联。据我们所知,这是第一项使用双标记方法的心血管组织工程体内研究,以证明共培养并同时预先接种的成年祖细胞的来源、持久性以及整合到TE血管补片中的直接证据。